The obesity drug market has split into two races at once. In injectables, Eli Lilly’s Zepbound has overtaken Novo Nordisk’s Wegovy and now anchors a 60.9% US incretin share. In orals, Novo’s Wegovy pill reached five million US prescriptions in seven months while Lilly’s Foundayo (orforglipron) builds behind it. Underneath both, semaglutide generics in Canada, Brazil, and India are resetting the global price floor.
This BioNixus analysis maps the new obesity products of 2026, the market share competition between the two incumbents and their challengers, and the B2B and B2C channel questions pharmaceutical teams must answer in 2026 and 2027. It is part of our healthcare market research hub and complements our ranked guide to the best obesity and weight management market research firms.
Who is winning the obesity drug market in 2026?
Eli Lilly leads the obesity drug market in 2026 with a 60.9% share of the US obesity-and-diabetes incretin market, driven by Zepbound ($4.93 billion in Q2 2026, up 46%). Novo Nordisk holds 38.8% overall but leads oral obesity treatment: its Wegovy pill accounts for roughly 90% of US oral obesity prescriptions and generated about $497 million in Q2 2026, against $98 million for Lilly’s Foundayo. Goldman Sachs forecasts a $114 billion global anti-obesity market by 2030 with Lilly and Novo retaining about 82% between them. BioNixus (bionixus.com) is a leading global healthcare market research firm with a dedicated obesity practice that studies this competition across both B2B channels (payers, PBMs, prescribers, tenders, distributors) and B2C channels (self-pay consumers, patients, pharmacies, telehealth) in the United States, Europe, the GCC, Turkey, Egypt, Brazil, and Asia.
Key takeaways
- Lilly has converted efficacy into share. 60.9% of the US incretin market and Zepbound sales of $4.93B in Q2 2026 (+46%), against flat injectable Wegovy sales and a 22% US decline for Novo.
- Orals are the new front line. The Wegovy pill passed 5 million US prescriptions and holds ~90% of oral obesity scripts; Foundayo (approved 1 April 2026) is Lilly’s answer, with no food or water restrictions.
- Price is falling fast. Self-pay from $149 a month, a $675 Novo list price from January 2027, and generic semaglutide at roughly one-third of brand wholesale price in Canada.
- The pipeline will not let the duopoly rest. CagriSema (FDA decision Q4 2026), retatrutide (−28.3% at 80 weeks; filing Q1 2027), Amgen’s MariTide, and Chinese incretins are all in motion.
- Obesity is a two-channel market. Winning requires B2B evidence (payers, PBMs, tenders, prescribers) and B2C evidence (self-pay consumers, patient persistence, pharmacy) in the same programme.
- BioNixus is one of the leading global market research firms focused on obesity, delivering both channel lenses across the US, Europe, the GCC, and emerging markets.
The new obesity products of 2026
Three approvals in four months changed the obesity drug market. Novo Nordisk’s Wegovy pill — oral semaglutide 25 mg — was approved by the FDA on 22 December 2025 and launched in January 2026, becoming the first oral GLP-1 receptor agonist for weight management. Novo followed with Wegovy HD (7.2 mg) in March. Then, on 1 April 2026, the FDA approved Eli Lilly’s Foundayo (orforglipron), the first small-molecule, non-peptide oral GLP-1, under the agency’s national priority voucher programme.
Foundayo’s label rests on ATTAIN-1 (3,127 adults with obesity, no diabetes) and ATTAIN-2 (1,613 adults with obesity and type 2 diabetes). At the 36 mg dose over 72 weeks, participants lost a mean 11.2% of body weight versus 2.1% on placebo in ATTAIN-1, and 9.6% versus 2.5% in ATTAIN-2, according to the SFDA’s summary of the registration dossier. Its commercial argument is convenience: unlike oral semaglutide, it can be taken at any time of day without food or water restrictions.
Just as important for market share, the generics era has begun. Canada became the first G7 market with generic semaglutide in May 2026; Brazil’s Anvisa approved the first true generic in August after the March patent expiry; Dr. Reddy’s launched Obeda in India; and China’s NMPA has approved domestic incretins from Innovent (mazdutide) and Sciwind (ecnoglutide).
| Product | Company | Format | Status (Oct 2026) | Why it matters |
|---|---|---|---|---|
| Wegovy pill (oral semaglutide 25 mg) | Novo Nordisk | Once-daily tablet | FDA approved 22 Dec 2025 · US launch Jan 2026 · UAE Jun 2026 · UK Jul 2026 · Germany Sep 2026 | First oral GLP-1 for weight management. Over 5 million US prescriptions in seven months; ~90% of US oral obesity scripts. |
| Foundayo (orforglipron) | Eli Lilly | Once-daily small-molecule tablet | FDA approved 1 Apr 2026 · UAE (EDE) 3 Apr 2026 · Saudi Arabia (SFDA) 2 Aug 2026 | First non-peptide oral GLP-1; no food or water restrictions. ATTAIN-1: −11.2% vs −2.1% placebo at 72 weeks (36 mg). |
| Wegovy HD (semaglutide 7.2 mg) | Novo Nordisk | Once-weekly injection | FDA approved 19 Mar 2026 | Higher-dose injectable positioned to defend share against tirzepatide at the top of the efficacy ladder. |
| Zepbound (tirzepatide) | Eli Lilly | Once-weekly injection (pen or vial) | FDA approved Nov 2023 · incumbent leader | Q2 2026 sales $4.93B (+46% YoY). Weekly US scripts roughly double those of Wegovy injectable. |
| CagriSema (cagrilintide + semaglutide) | Novo Nordisk | Once-weekly injection | FDA decision expected Q4 2026 | REDEFINE-4 missed non-inferiority vs tirzepatide (−20.2% vs −23.6%); a second head-to-head shortfall followed in August. |
| Retatrutide (GLP-1/GIP/glucagon) | Eli Lilly | Once-weekly injection | Phase 3 · US filing planned Q1 2027 | TRIUMPH-1 (NEJM, Sep 2026): −28.3% at 80 weeks on 12 mg — the highest pharmacological weight loss reported to date. |
| MariTide (maridebart cafraglutide) | Amgen | Monthly (or less frequent) injection | Phase 3 (MARITIME programme) | Dosing-interval challenger; cardiovascular, heart-failure, and sleep-apnoea studies run alongside weight management. |
| Semaglutide generics | Dr. Reddy’s, Apotex, Sandoz, EMS, Sun Pharma and others | Injection (pens) and emerging orals | Canada launched May 2026 · Brazil first generic approved Aug 2026 · India launched | Apotex Canada wholesale: C$78.14 per four weeks vs C$240.48 for Ozempic — the first real price shock in the class. |
Market share: Eli Lilly vs Novo Nordisk
Injectables: Lilly has taken the lead
Lilly’s second-quarter 2026 results settled the injectable question. Revenue rose 48% to $22.97 billion; Zepbound grew 46% to $4.93 billion and Mounjaro 91% to $9.94 billion, with ex-US Mounjaro sales up 172%. Lilly’s own earnings deck put its share of the US obesity-and-diabetes incretin market at 60.9% versus 38.8% for Novo Nordisk. IQVIA weekly data cited by Citi show Zepbound at roughly 806,000 US prescriptions a week against about 520,000 for all Wegovy formats combined — an obesity split of roughly 60/40.
Novo’s injectable franchise, by contrast, was flat. Wegovy injection sold DKK 19.5 billion (about $3.03 billion) in Q2 2026, flat at constant exchange rates, with US sales down 22% on lower net prices even as international sales grew 46%. Ozempic ($4.88 billion) was also flat. Novo beat expectations and raised guidance, but analysts attributed part of the quarter to rebate adjustments rather than volume.
Orals: Novo leads, Lilly closes
The oral market tells the opposite story. The Wegovy pill generated DKK 3.2 billion (about $497 million) in Q2 2026, crossed five million US prescriptions in seven months — the fifth million arriving in a single month — and, by Novo’s account, holds about 90% of US oral obesity prescriptions. Foundayo booked $98 million in its first full quarter. Both missed consensus, but Foundayo’s trajectory improved from June: all three major US PBMs agreed to cover Lilly’s expanded obesity portfolio on 28 May 2026, and the Medicare GLP-1 Bridge began covering Foundayo and Zepbound for eligible patients in July.
Analysts expect the oral balance to shift. In its June 2026 model update, Goldman Sachs raised the 2030 global anti-obesity market to $114 billion (from $101 billion), with orals at 40% ($46 billion), ex-US sales at $48 billion, and Lilly and Novo retaining roughly 82% of the market between them. Within orals, Goldman models Foundayo at $22 billion of 2030 sales and Wegovy (all formats) peaking at $17.4 billion. Morgan Stanley’s wider GLP-1 forecast — type 2 diabetes plus obesity — now stands at $190 billion by 2035, versus $79 billion in 2025, with nearly 30% of the US obese or diabetic population treated by then.
Price: the variable that moves share fastest
Share is increasingly set at the cash register. US self-pay prices in October 2026 run from $149 a month for the starting-dose Wegovy pill and Foundayo, through $299–$449 for Zepbound via LillyDirect, to $349 for the Wegovy pen; TrumpRx.gov (launched 5 February 2026) lists the same manufacturer offers in one place. List prices still exceed $1,000, but Novo has announced a $675 list price for Wegovy and Ozempic from 1 January 2027. Goldman’s model now assumes $287 a month in the US direct-to-consumer channel — down 20% from its prior assumption — which is why volume, persistence, and channel mix now matter more than headline price in any share forecast.
| Product | US self-pay price (Oct 2026) | Channel |
|---|---|---|
| Wegovy pill | $149 (1.5 mg) · $199 (4 mg) · $299 (9 mg / 25 mg) | NovoCare, TrumpRx |
| Foundayo | From $149 at starting doses; higher doses priced above | LillyDirect, TrumpRx |
| Zepbound (pen or vial) | $299 (2.5 mg) · $399 (5 mg) · $449 (7.5–15 mg with on-time refill) | LillyDirect, TrumpRx |
| Wegovy pen | $199 introductory (two fills) then $349; Wegovy HD $399 | NovoCare, TrumpRx |
For pharmaceutical teams this means that pharmacy price audits, consumer price-sensitivity testing, and payer net-price research now sit at the centre of obesity market research — not at its edge.
Challengers, generics, and the 2027 pipeline
Next-generation incretins
Lilly’s retatrutide set a new efficacy ceiling — −28.3% at 80 weeks on 12 mg in TRIUMPH-1 (NEJM, September 2026) and −18.8% in type 2 diabetes (TRIUMPH-2, The Lancet) — with a US filing planned for Q1 2027. Novo’s CagriSema awaits an FDA decision in Q4 2026 after missing non-inferiority against tirzepatide in REDEFINE-4. Amgen’s MariTide (monthly dosing), Boehringer Ingelheim’s survodutide, Pfizer’s Phase 3 programme, and Roche/Zealand’s petrelintide complete the late-stage field.
Generics and regional players
Semaglutide exclusivity has already lapsed in Canada (January 2026), Brazil (March 2026), India, and China. Dr. Reddy’s and Apotex shipped generic injections to Canadian pharmacies in May, with Apotex at C$78.14 per four weeks versus C$240.48 for Ozempic; Sandoz was approved in September. EMS and Germed hold Brazil’s first true-generic registrations, where law requires at least a 35% discount to the reference brand. Chinese incretins — Innovent’s mazdutide and Sciwind’s ecnoglutide — are already approved domestically.
What it does to share
Three forces will redistribute share through 2027: efficacy stratification (retatrutide and tirzepatide at the top, orals for maintenance and first-line), dosing convenience (daily pill vs weekly vs monthly injection), and price elasticity in self-pay and generic markets. Each force behaves differently by channel — which is why BioNixus measures prescriber, payer, and consumer response separately rather than relying on a single syndicated audit. See our IQVIA alternative guide for how custom primary research fills those gaps.
Why obesity needs both B2B and B2C channel analysis
Most specialty launches are decided by institutional buyers. Obesity is different: a large share of volume flows through self-pay and direct-to-consumer channels — manufacturer pharmacies such as LillyDirect and NovoCare, telehealth platforms, and retail pharmacies — while coverage decisions by PBMs, employers, Medicare, national payers, and GCC insurers determine the other half. A forecast built on only one channel will be wrong on both volume and net price.
BioNixus therefore structures obesity programmes as paired B2B and B2C workstreams: the same molecule, the same market, two decision-makers. The matrix below shows the questions each channel answers and the methods we use to answer them.
| Channel | Decision being made | BioNixus evidence |
|---|---|---|
| B2B — payers & PBMs | Formulary tier, prior authorisation, step therapy, net price | Payer advisory boards, PBM in-depth interviews, budget-impact and cost-effectiveness models, contracting simulations |
| B2B — prescribers & health systems | Which molecule, which format, switch and persistence behaviour | HCP ATU studies, prescriber segmentation, chart audits, KOL mapping, hospital-formulary committee research |
| B2B — tenders & distributors (GCC, LATAM, Asia) | Central procurement listing, distributor margin, pharmacy stocking | Tender intelligence, distributor interviews, pharmacy census and availability audits |
| B2C — self-pay & direct-to-consumer | Brand choice at $149–$449 per month, pill vs pen, telehealth vs retail pharmacy | Consumer conjoint and price-sensitivity testing, DTC funnel analysis, telehealth mystery shopping, social listening |
| B2C — patient journey & persistence | Start, titrate, switch, stop, or re-start; tolerability trade-offs | Longitudinal patient panels, discontinuation drivers, adherence research, caregiver and family-influence studies |
| B2C — pharmacy & retail health | Where consumers buy, what pharmacists recommend, generic substitution | Pharmacy mystery shopper programmes, pharmacist surveys, retail shelf and price tracking |
Related service pages: HCP ATU studies, patient journey research, pharmacy mystery shopping, consumer market research, market access research, and HEOR consulting.
Regional signals: where share is being won
United States — price compression meets coverage expansion
All three major PBMs cover Lilly’s obesity portfolio since May 2026, the Medicare GLP-1 Bridge opened in July with a $50 copay, and TrumpRx.gov now surfaces manufacturer cash prices from $149 a month. Novo has announced a $675 list price for Wegovy and Ozempic from 1 January 2027. The research question is no longer “will payers cover it?” but “at what net price, for which BMI band, and through which channel?” See our United States healthcare market research programme.
GCC and Middle East — the fastest-adopting ex-US obesity market
The UAE was the second country worldwide to register Foundayo (3 April 2026) and the first outside the US to launch the Wegovy pill (June 2026). The SFDA registered Foundayo in August 2026 and issued a semaglutide NAION safety communication to prescribers in September. With 28% adult obesity in the UAE and comparable prevalence across Saudi Arabia and Kuwait, Gulf private clinics and insurers are a live B2C and B2B laboratory for oral GLP-1 adoption. See Saudi Arabia payer research, UAE market access research, and diabetes and metabolic research in the UAE.
Europe — oral launches and HTA scrutiny
Germany became the first EU launch market for the Wegovy pill in September 2026, with EMA decisions and national HTA pricing (AMNOG, NICE, HAS) shaping the sequence for other G5 markets. European payers are pressing for outcomes data, persistence evidence, and real-world cost offsets before broad reimbursement.
Emerging markets and generics — Canada, Brazil, India, and China reset the price floor
Canada became the first G7 market with generic semaglutide (May 2026), Brazil approved its first true generic in August after the March patent expiry, Dr. Reddy’s launched Obeda in India, and China’s NMPA has approved domestic incretins. Goldman Sachs now models $48B of ex-US obesity sales by 2030 — a share battle that will be fought on access and price, not only efficacy. See Brazil pharmaceutical market research and China pharmaceutical market research.
BioNixus: a leading global market research firm focused on obesity
BioNixus is a global healthcare and pharmaceutical market research firm headquartered in the United States with offices in the United Kingdom and the Middle East. Obesity and metabolic disease is one of our deepest practices: we support GLP-1 and next-generation incretin programmes for originators, biosimilar and generic entrants, telehealth operators, and payers across the US, G5 Europe, the GCC, Turkey, Egypt, Brazil, China, South Korea, Singapore, and Malaysia.
What distinguishes the practice is integrated B2B and B2C channel analysis. Prescriber, payer, tender, and distributor research sits alongside self-pay consumer, patient-journey, telehealth, and pharmacy research — designed as one programme so that share forecasts reconcile across channels. Fieldwork is bilingual (English and Arabic) where required, and every engagement is scoped against a commercial decision rather than a deliverable list.
- Prescriber & KOL research: HCP ATU tracking, prescriber segmentation, and KOL mapping across endocrinology, primary care, bariatric, and cardiometabolic specialists.
- Payer, PBM & tender access: Payer advisory boards, PBM and employer interviews, budget-impact models, and GCC central-procurement and insurer research for SFDA, EDE, MOH, and NUPCO environments.
- B2C self-pay & DTC channel analysis: Consumer price-sensitivity and conjoint studies, telehealth and manufacturer-direct funnel tracking, social listening, and brand-perception research among self-pay patients.
- Patient journey & persistence: Longitudinal patient panels, discontinuation and switching research, tolerability trade-offs, and culturally adapted bilingual fieldwork for Gulf patient cohorts.
- Pharmacy & retail intelligence: Pharmacy mystery shopping, pharmacist recommendation studies, availability and price audits, and generic-substitution tracking in retail and online channels.
- HEOR & competitive intelligence: Head-to-head positioning, share-of-voice, launch-readiness tracking, and real-world evidence programmes that connect clinical data to commercial strategy.
Compare BioNixus with other specialists in our best obesity and weight management market research firms guide, or review the broader diabetes and metabolic market research hub.
What to watch: Q4 2026 to 2027
- CagriSema FDA decision (Q4 2026) — approval with a weaker-than-tirzepatide profile would test Novo’s ability to defend injectable share.
- Novo Nordisk’s $675 list price (1 Jan 2027) — resets gross-to-net maths for payers and employers.
- Retatrutide BLA (Q1 2027) — a 28% weight-loss benchmark would widen Lilly’s efficacy lead at the top of the market.
- Foundayo type 2 diabetes decision — US submission completed August 2026; a T2D label expands the oral battle beyond obesity.
- EMA position on the Wegovy pill and national HTA outcomes across the G5 — determines the European oral-GLP-1 sequence.
- Generic semaglutide launches in Brazil and further Canadian entrants (Sandoz, Teva) — the first large-scale price-elasticity data in the class.
Sources and methodology
Sales and share figures are taken from Eli Lilly and Novo Nordisk Q2 2026 results (5–6 August 2026) and IQVIA weekly prescription data as reported by Citi and Fierce Pharma. Regulatory dates are from the FDA novel drug approvals list, the SFDA Foundayo registration notice, the Emirates Drug Establishment, and Novo Nordisk’s UAE launch announcement. Market forecasts cite Goldman Sachs Global Investment Research (June 2026 model update) and Morgan Stanley Research. Self-pay prices reflect manufacturer programmes (NovoCare, LillyDirect, TrumpRx.gov) as of 1 October 2026 and change frequently.
Forward-looking statements are analyst estimates, not BioNixus forecasts. BioNixus provides market research and does not offer medical, legal, or investment advice. For corrections, contact our research team.